# BEFORE THE APPLICATION REVIEW SUBCOMMITTEE AND THE INDEPENDENT CITIZENS' OVERSIGHT COMMITTEE TO THE

# CALIFORNIA INSTITUTE FOR REGENERATIVE MEDICINE ORGANIZED PURSUANT TO THE CALIFORNIA STEM CELL RESEARCH AND CURES ACT

#### REGULAR MEETING

LOCATION: AS INDICATED ON THE AGENDA

DATE: TUESDAY, JANUARY 19, 2016

11 A.M.

REPORTER: BETH C. DRAIN, CSR

CSR. NO. 7152

BRS FILE NO.: 98253

#### INDEX

ITEM DESCRIPTION	PAGE	NO.
REPORTS & DISCUSSION ITEMS		
1. CALL TO ORDER.		3
2. PLEDGE OF ALLEGIANCE.		
3. ROLL CALL.		3
CONSENT CALENDAR ITEMS 4 AND 5:		5
4. CONSIDERATION OF APPOINTMENT OF NEW SCIENTIFIC MEMBERS TO THE GRANTS WORKING GROUP.		
5. CONSIDERATION OF MINUTES FOR SEPTEMBER, OCTOBER, NOVEMBER AND DECEMBER 2015 BOARD MEETINGS.		
ACTION ITEMS		
6. CONSIDERATION OF APPLICATIONS SUBMITTED IN RESPONSE TO PA: EDUC 2 BRIDGES AND PA: EDUC3 SPARK APPLICATIONS.		7
7. CONSIDERATION OF ADOPTION OF INTERIM GRANTS ADMINISTRATION POLICY FOR THE DISCOVERY, TRANSLATIONAL AND EDUCATION PROGRAMS.		20
CLOSED SESSION	NO	NE
8. DISCUSSION OF CONFIDENTIAL INTELLECTUAL POR WORK PRODUCT, PREPUBLICATION DATA, FINANCINFORMATION, CONFIDENTIAL SCIENTIFIC RESEARCDATA, AND OTHER PROPRIETARY INFORMATION RELAAPPLICATIONS EDUC 2 (15-05) AND EDUC 3 (15-0 (HEALTH & SAFETY CODE 125290.30(F)(3)(B) AND	TAL THOR TING	то
PUBLIC COMMENT	NO	NE

2

1	TUESDAY, JANUARY 19, 2016; 11 A.M.
2	
3	CHAIRMAN THOMAS: WELCOME, EVERYONE, TO
4	THE APPLICATION REVIEW SUBCOMMITTEE. WE'RE IN
5	BEAUTIFUL, RAINY OAKLAND THIS MORNING. AND THANK
6	YOU ALL FOR PARTICIPATING. SO, AMY, WILL YOU PLEASE
7	CALL THE ROLL.
8	MS. CHEUNG: DAVID BRENNER.
9	DR. BRENNER: HERE.
10	MS. CHEUNG: LINDA BOXER.
11	DR. BOXER: HERE.
12	MS. CHEUNG: KEN BURTIS.
13	DR. BURTIS: PRESENT.
14	MS. CHEUNG: ANNE-MARIE DULIEGE.
15	DR. DULIEGE: PRESENT.
16	MS. CHEUNG: MICHAEL FRIEDMAN.
17	DR. FRIEDMAN: HERE.
18	MS. CHEUNG: JUDY GASSON. SAM HAWGOOD.
19	DAVID HIGGINS. STEPHEN JUELSGAARD. SHERRY LANSING.
20	KATHY LAPORTE. BERT LUBIN.
21	DR. LUBIN: HERE.
22	MS. CHEUNG: SHLOMO MELMED. LAUREN
23	MILLER.
24	MS. MILLER: HERE.
25	MS. CHEUNG: ADRIANA PADILLA. JOE
	3
	3

1	PANETTA.
2	MR. PANETTA: HERE.
3	(INTERRUPTION IN PROCEEDINGS.)
4	MS. CHEUNG: ROBERT PRICE.
5	DR. PRICE: HERE.
6	MS. CHEUNG: FRANCISCO PRIETO.
7	DR. PRIETO: HERE.
8	MS. CHEUNG: CARMEN PULIAFITO. ROBERT
9	QUINT. AL ROWLETT.
10	MR. ROWLETT: HERE.
11	MS. CHEUNG: JEFF SHEEHY.
12	MR. SHEEHY: HERE.
13	MS. CHEUNG: OS STEWARD.
14	DR. STEWARD: HERE.
15	MS. CHEUNG: JONATHAN THOMAS.
16	CHAIRMAN THOMAS: HERE.
17	MS. CHEUNG: ART TORRES.
18	MR. TORRES: HERE.
19	MS. CHEUNG: KRISTINA VUORI.
20	DR. VUORI: HERE.
21	MS. CHEUNG: DIANE WINOKUR.
22	MR. JUELSGAARD: ANY, THIS IS STEVE
23	JUELSGAARD. I JOINED A LITTLE WHILE AGO. THIS HAS
24	BEEN ONE OF THE MOST DIFFICULT CALLS TO JOIN. I
25	DON'T KNOW IF YOU CHANGED THE SYSTEM OR WHAT, BUT IT
	4

1	WAS NOT EASY TO GET THROUGH.
2	MS. CHEUNG: I'LL LOOK INTO THAT FOR THE
3	NEXT CALL.
4	DR. HIGGINS: THIS IS DAVID HIGGINS. I'VE
5	ALSO BEEN HAVING TROUBLE.
6	DR. MELMED: ARE YOU HEARING US.
7	MS. CHEUNG: DR. MELMED, WAS THAT YOU.
8	DR. MELMED: YES, THAT WAS ME. I ANSWERED
9	EARLIER AND YOU NEVER HEARD.
10	MS. BONNEVILLE: NOW WE CAN.
11	CHAIRMAN THOMAS: OKAY. THANK YOU,
12	EVERYBODY. THE FIRST ITEMS ON THE AGENDA ARE
13	CONSENT ITEMS. IF WE DON'T HAVE ANY MEMBERS WHO
14	WANT TO PULL AND DISCUSS SEPARATELY, I WOULD
15	ENTERTAIN A MOTION TO APPROVE ITEMS 4 AND 5.
16	MR. SHEEHY: SO MOVED.
17	DR. JUELSGAARD: I SO MOVE.
18	CHAIRMAN THOMAS: MOVED BY MR. SHEEHY,
19	SECONDED BY MR. JUELSGAARD. ANY COMMENTS FROM
20	MEMBERS OF THE BOARD? VOICE VOTE ON THIS ONE.
21	MR. HARRISON: YOU NEED TO DO A ROLL CALL.
22	CHAIRMAN THOMAS: AMY, PLEASE CALL THE
23	ROLL.
24	MS. CHEUNG: DAVID BRENNER.
25	DR. BRENNER: YES.
	F
	5

-		
1		MS. CHEUNG: LINDA BOXER.
2		DR. BOXER: YES.
3		MS. CHEUNG: KEN BURTIS.
4		DR. BURTIS: YES.
5		MS. CHEUNG: ANNE-MARIE DULIEGE.
6		DR. DULIEGE: YES.
7		MS. CHEUNG: MICHAEL FRIEDMAN.
8		DR. FRIEDMAN: YES.
9		MS. CHEUNG: JUDY GASSON.
10		DR. GASSON: YES.
11		MS. CHEUNG: SAM HAWGOOD. DAVID HIGGINS.
12		DR. HIGGINS: YES.
13		MS. CHEUNG: STEPHEN JUELSGAARD.
14		MR. JUELSGAARD: YES.
15		MS. CHEUNG: SHERRY LANSING. KATHY
16	LAPORTE.	BERT LUBIN.
17		DR. LUBIN: YES.
18		MS. CHEUNG: SHLOMO MELMED.
19		DR. MELMED: YES.
20		MS. CHEUNG: LAUREN MILLER.
21		MS. MILLER: YES.
22		MS. CHEUNG: ADRIANA PADILLA.
23		DR. PADILLA: YES.
24		MS. CHEUNG: JOE PANETTA.
25		MR. PANETTA: YES.
		6

```
1
               MS. CHEUNG: ROBERT PRICE.
 2
                DR. PRICE: YES.
 3
               MS. CHEUNG: FRANCISCO PRIETO.
 4
               MS. CHEUNG: AYE.
 5
               MS. CHEUNG: CARMEN PULIAFITO. ROBERT
 6
     OUINT.
             AL ROWLETT.
 7
               MR. ROWLETT: YES.
 8
               MS. CHEUNG: JEFF SHEEHY.
 9
               MR. SHEEHY: YES.
10
               MS. CHEUNG: OS STEWARD.
11
               DR. STEWARD: YES.
12
               MS. CHEUNG: JONATHAN THOMAS.
13
               CHAIRMAN THOMAS: YES.
14
               MS. CHEUNG: ART TORRES.
15
               MR. TORRES: AYE.
16
               MS. CHEUNG: KRISTINA VUORI.
17
               DR. VUORI: YES.
18
               MS. CHEUNG: DIANE WINOKUR.
19
               CHAIRMAN THOMAS: THANK YOU. WE'RE NOW
20
     GOING TO ASK TO GO ON TO ITEM NO. 6, WHICH IS THE
21
     BRIDGES AND SPARK PROGRAMS. GOING TO TURN IT OVER
22
     TO DR. SAMBRANO.
               DR. SAMBRANO: THANK YOU, MR. CHAIRMAN.
23
24
     SO I'M GOING TO GO THROUGH THIS PRESENTATION, AND
25
     IT'S DIVIDED INTO TWO SEGMENTS. SO WE'RE GOING TO
                               7
```

1	GO THROUGH THE BRIDGES OVERVIEW AND THEN
2	CONSIDERATION OF THOSE APPLICATIONS, AND THEN WE'LL
3	FOLLOW THAT WITH THE SPARK PROGRAM.
4	SO THAT IS THE ORDER OF THE PRESENTATION
5	TODAY. LET ME GIVE YOU AN OVERVIEW ON THE BRIDGES
6	PROGRAM. SO AS MOST OF YOU KNOW, THE BRIDGES
7	PROGRAM HAS BEEN AROUND FOR A WHILE NOW. SO IT WAS
8	ORIGINALLY A THREE-YEAR PROGRAM THAT WAS RENEWED FOR
9	ANOTHER THREE YEARS, AND THEN ONE THE LAST YEAR OVER
10	THE COURSE OF THIS YEAR FOR A TOTAL OF SEVEN YEARS
11	THAT THIS PROGRAM HAS BEEN IN EXISTENCE WITH A TOTAL
12	OF 16 PROGRAMS, 13 OF THOSE CALIFORNIA STATE
13	UNIVERSITIES AND THREE COMMUNITY COLLEGES.
14	WE HAVE HAD GREATER THAN 700 STUDENTS THAT
15	HAVE COMPLETED THE PROGRAM AND HAVE OVERALL DONE
16	PRETTY WELL IN TERMS OF OUTCOMES. PURSUANT TO A
17	SURVEY THAT WAS DONE A COUPLE OF YEARS AGO, ABOUT 50
18	PERCENT ARE WORKING IN LAB JOBS, 30 PERCENT BECAME
19	ENROLLED IN A GRADUATE OR PROFESSIONAL SCHOOL, AND
20	15 ARE COMPLETING AN EDUCATION PROGRAM OR APPLYING.
21	AND MANY OF THEM HAVE BEEN EMPLOYED FULL
22	TIME IN MANY OF THE LABS. A LOT OF TIMES THE LABS
23	WHERE THEY WERE MENTORED ORIGINALLY. AND THIS
24	COVERS GREATER THAN 20 CALIFORNIA UNIVERSITIES AND
25	RESEARCH INSTITUTES AND GREATER THAN 50 BIOTECH AND
	8
	lacksquare

1	PHARMACEUTICAL COMPANIES.
2	SO THAT WAS THE BRIDGES 1.0, AS WE WOULD
3	CALL IT. BUT AS WE VENTURED INTO CIRM 2.0, WE
4	WANTED TO THINK ABOUT HOW TO RESTRUCTURE THIS
5	PROGRAM TO ALIGN IT WITH OUR MISSION. AND SO THIS
6	IS THE RESULT OF THE CONCEPT THAT WAS PRESENTED TO
7	YOU SEVERAL MONTHS AGO WITH THE OBJECTIVE OF
8	CONTINUING TO FOCUS ON UNDERGRADUATE AND MASTER'S
9	LEVEL STUDENTS AND TO HELP THEM DEVELOP CAREERS IN
10	STEM CELL RESEARCH AND THERAPY DEVELOPMENT.
11	OF COURSE, THERE'S A LOT OF THINGS THAT
12	ARE BEING KEPT AS PART OF THIS PROGRAM, CERTAINLY
13	THE INTERNSHIP COMPONENT, WHICH IS USUALLY ABOUT 12
14	MONTHS, STEM CELL TRAINING COURSE, EDUCATIONAL
15	ENHANCEMENT ACTIVITIES, AND THE BROADENING OF
16	PARTICIPATION FROM UNDERREPRESENTED STUDENT
17	POPULATIONS.
18	THERE ARE SEVERAL THINGS THAT WE ARE
19	ADDING, HOWEVER, TO TRY TO ALIGN WITH THE MISSION.
20	THESE INCLUDE DIRECT PATIENT ENGAGEMENT ACTIVITIES,
21	FORMAL TRAINING ON THE REGULATORY PATHWAY AND
22	DEVELOPMENT PROCESS, COMMUNITY OUTREACH ACTIVITIES,
23	AND CAREER COUNSELING FOR THE TRAINEES AND ALUMNI.
24	SO THESE ARE ALL NEW ELEMENTS; AND ALTHOUGH WE MAY
25	HAVE HAD EXISTING PROGRAMS THAT HAVE REAPPLIED, THEY

1	ARE IN THE PROCESS OF REAPPLYING TO ADDRESS THESE
2	NEW COMPONENTS.
3	SO WHO CAN APPLY? SO THIS WAS CALIFORNIA
4	UNIVERSITIES AND COLLEGES THAT DON'T HAVE A MAJOR
5	STEM CELL RESEARCH PROGRAM; THAT IS, A MAJOR
6	FACILITIES THE SAME AS IT WAS IN THE ORIGINAL
7	PROGRAM, BUT IS OPEN TO BOTH THESE PREEXISTING
8	BRIDGES PROGRAMS AND POTENTIALLY NEW PROGRAMS.
9	SEVERAL MONTHS AGO THE BOARD APPROVED UP
10	TO 45.7 MILLION TO SUPPORT UP TO ABOUT 15 PROGRAMS,
11	AND EACH AWARD WOULD SUPPORT TEN TRAINEES PER YEAR.
12	THESE PROGRAMS WOULD EXIST, IF APPROVED, FOR UP TO
13	FIVE YEARS EACH.
14	LET ME TELL YOU AND REMIND YOU A LITTLE
15	BIT ABOUT THE SCORING. THIS IS WHAT WE MIGHT REFER
16	TO NOW AS THE OLD SCORING SYSTEM THAT WAS USED IN
17	THIS REVIEW. SO THE SCALE WAS FROM 1 TO 100. AND A
18	SCORE OF 75 TO 100 BEING EXCEPTIONAL MERIT AND
19	WARRANTS FUNDING. IF IT'S A SCORE BETWEEN 65 AND
20	74, THAT'S MODERATE QUALITY OR NO CONSENSUS, BUT
21	SUITABLE FOR PROGRAMMATIC CONSIDERATION, AND 64 AND
22	BELOW MEANS THAT IT IS SUFFICIENTLY FLAWED AND IT
23	DOES NOT WARRANT FUNDING. SO THOSE ARE THE BASIS OF
24	THE SCORES.
25	I ALSO WANT TO GIVE YOU A LITTLE BIT OF

1	CONTEXT WITH THE REVIEW. THIS APPLIES BOTH TO THE
2	BRIDGES AND THE SPARK. DURING THE COURSE OF THE
3	DISCUSSION AND THE REVIEW, MANY OF THE REVIEWERS
4	MADE OBSERVATIONS AND PROVIDED SUGGESTIONS THAT
5	REALLY IMPACT ON ALL THE PROGRAMS, THOUGH SOME OF
6	THEM WERE BROUGHT UP UNDER SPECIFIC PROGRAMS AND
7	THOSE ARE, IN PART, CAPTURED IN THE SUMMARIES, BUT
8	IT WAS ALSO MADE CLEAR TO REVIEWERS THAT UPON
9	LAUNCHING THE NEW AWARDS, WE WOULD BE BRINGING
10	PROGRAM DIRECTORS ON THE APPROVED PROGRAMS TOGETHER
11	TO DISCUSS WAYS OF IMPROVING AND UNIFYING THE
12	PROGRAM. FOR EXAMPLE, THE COLLECTION AND TRACKING
13	OF DATA OF TRAINEES AND THEIR PROGRESS AND WHERE
14	THEY GO. IF WE CAN DO THAT IN A UNIFORM WAY ACROSS
15	ALL THE DIFFERENT PROGRAMS, I THINK THAT WOULD BE
16	HELPFUL TO CIRM IN TERMS OF REPORTING ON SUCCESS OF
17	THESE PROGRAMS. I JUST WANTED TO LET YOU KNOW THAT.
18	AND THEN, FINALLY, HERE'S THE SUMMARY OF
19	RECOMMENDATIONS FROM THE GRANTS WORKING GROUP.
20	THERE WERE A TOTAL OF 14 APPLICATIONS THAT WERE
21	RECOMMENDED FOR FUNDING FOR A FUNDING AMOUNT OF 40.1
22	MILLION. THERE'S ONE APPLICATION THAT IS IN TIER II
23	FOR 30 MILLION, AND THEN THERE ARE TWO NOTED THAT
24	WERE IN TIER III, ALTHOUGH ONE OF THEM WITHDREW
25	YESTERDAY. AND THAT WAS APPLICATION 84-28, THE ONE
	11

1	LISTED LAST ON THE SPREADSHEET. SO AT THIS POINT WE
2	LOOK FORWARD TO CONSIDERING THESE RECOMMENDATIONS
3	FOR BRIDGES PROGRAM.
4	CHAIRMAN THOMAS: THANK YOU VERY MUCH,
5	DR. SAMBRANO. JEFF, WOULD YOU TAKE IT FROM HERE
6	PLEASE?
7	MR. SHEEHY: SURE. SO I THINK IT'S BEEN
8	AWHILE SINCE WE'VE HAD THE THREE-TIER, BUT FOLLOWING
9	WHAT WE'VE DONE IN THE PAST, THE FIRST QUESTION IS
10	DO WE HAVE ANY MOTIONS TO MOVE ANYTHING FROM TIER
11	III INTO TIER I? OKAY.
12	THEN HEARING NONE, THEN DO WE HAVE ANY
13	MOTIONS TO MOVE THE ITEM IN TIER II INTO TIER I.
14	HEARING NONE, DO WE HAVE A MOTION TO
15	APPROVE FUNDING FOR ALL OF THE APPLICATIONS IN TIER
16	I AND NOT TO FUND ANY OF THE REMAINING APPLICATIONS?
17	MR. ROWLETT: SO MOVED.
18	MR. SHEEHY: DO WE HAVE A SECOND.
19	MR. TORRES: SECOND.
20	MR. SHEEHY: OKAY. DO WE HAVE ANY PUBLIC
21	AT ANY OF THE SITES? NO. DO WE HAVE ANY BOARD
22	COMMENT? THEN, AMY, COULD YOU CALL THE ROLL ON THE
23	MOTION PLEASE.
24	MS. CHEUNG: ANNE-MARIE DULIEGE.
25	DR. DULIEGE: YES.
	13
	12

1		MS. CHEUNG: DAVID HIGGINS.
2		DR. HIGGINS: YES.
3		MS. CHEUNG: STEPHEN JUELSGAARD. SHERRY
4	LANSING.	KATHY LAPORTE. LAUREN MILLER.
5		MS. MILLER: YES.
6		MS. CHEUNG: ADRIANA PADILLA.
7		DR. PADILLA: YES.
8		MS. CHEUNG: JOE PANETTA.
9		MR. PANETTA: YES.
10		MS. CHEUNG: FRANCISCO PRIETO.
11		DR. PRIETO: AYE.
12		MS. CHEUNG: ROBERT QUINT. AL ROWLETT.
13		MR. ROWLETT: YES.
14		MS. CHEUNG: JEFF SHEEHY.
15		MR. SHEEHY: YES.
16		MS. CHEUNG: OS STEWARD.
17		DR. STEWARD: YES.
18		MS. CHEUNG: JONATHAN THOMAS.
19		CHAIRMAN THOMAS: YES.
20		MS. CHEUNG: ART TORRES.
21		MR. TORRES: AYE.
22		MS. CHEUNG: DIANE WINOKUR.
23		MR. HARRISON: OS, YOU SHOULD VOTE YES
24	EXCEPT WI	TH RESPECT TO THOSE IN WHICH YOU HAVE A
25	CONFLICT.	
		12
		13

1	DR. STEWARD: MY APOLOGY. YES, EXCEPT FOR
2	THOSE WITH WHICH I HAVE A CONFLICT.
3	MR. SHEEHY: ALSO RESPONDING YES, EXCEPT
4	FOR THOSE WHICH I HAVE A CONFLICT.
5	MR. JUELSGAARD: AMY, THIS IS STEVE
6	JUESLGAARD. YES.
7	MR. HARRISON: MOTION PASSES.
8	DR. LUBIN: I WASN'T ASKED, BUT I WOULD
9	SAY YES, EXCEPT FOR THOSE WITH WHICH I HAVE A
10	CONFLICT.
11	MR. HARRISON: WE SHOULD CLARIFY. THIS
12	WAS A MOTION FOR THE APPLICATION REVIEW SUBCOMMITTEE
13	OF WHICH YOU ARE AN EX OFFICIO, NONVOTING MEMBER,
14	DR. LUBIN.
15	DR. LUBIN: THANK YOU.
16	CHAIRMAN THOMAS: GIL, CAN YOU CONTINUE
17	NOW WITH THE SPARK DESCRIPTION PLEASE.
18	DR. SAMBRANO: SO THE SPARKS PROGRAM,
19	FORMERLY KNOWN AS THE CREATIVITY PROGRAM, HAS BEEN
20	RUNNING FOR ABOUT FOUR YEARS. IT ORIGINALLY FUNDED
21	WITH 2.1 MILLION NINE PROGRAMS THAT ARE ABOUT EVENLY
22	SPLIT BETWEEN NORTHERN AND SOUTHERN CALIFORNIA. SO
23	RELATIVELY SPEAKING, THIS IS A MORE INEXPENSIVE
24	PROGRAM RELATIVE TO BRIDGES, BUT IT HAS SUPPORTED
25	MORE THAN 240 HIGH SCHOOL STUDENTS OVER THAT
	14
	14

1	FOUR-YEAR TIME PERIOD AND MORE THAN 45 HIGH SCHOOLS
2	THROUGHOUT CALIFORNIA FROM WHICH THE STUDENTS HAVE
3	BEEN SELECTED.
4	SIMILAR ON THE BRIDGES PROGRAM, WE THOUGHT
5	ABOUT HOW TO ALIGN THIS WITH THE MISSION OF CIRM
6	2.0. PART OF IT WAS RENAMING IT TO SPARK, SUMMER
7	PROGRAM TO ACCELERATE REGENERATIVE MEDICINE
8	KNOWLEDGE. AND THERE ARE ELEMENTS THAT WE KEPT, OF
9	COURSE, THE INTERNSHIP COMPONENT. IN ALL CASES THE
10	INTERNSHIPS AND THE PROGRAMS ARE A SUPPLEMENT TO AN
11	EXISTING PROGRAM. AND ONE OF THE OTHER THINGS THAT,
12	OF COURSE, WE ARE KEEPING IS BROADENING
13	PARTICIPATION OF UNDERREPRESENTED POPULATIONS, AND
14	THE FAMOUS POSTER DAY WHERE ALL THE STUDENTS COME
15	TOGETHER AT THE VERY END TO PRESENT THEIR FINDINGS
16	TO AN AUDIENCE.
17	THERE ARE THINGS THAT WE ARE ADDING THAT
18	ARE SIMILAR TO THAT IN BRIDGES: DIRECT PATIENT
19	ENGAGEMENT ACTIVITIES, PREPARATORY TRAINING COURSE
20	BEFORE COMMENCEMENT OF THE RESEARCH, AND COMMUNITY
21	OUTREACH ACTIVITIES.
22	SO THIS RFA WAS OPEN TO CALIFORNIA
23	UNIVERSITIES, COLLEGES, OR RESEARCH INSTITUTIONS
24	WITH AN ESTABLISHED HIGH SCHOOL SUMMER INTERNSHIP
25	PROGRAM, AS I MENTIONED PREVIOUSLY. THE ICOC
	15

1	APPROVED UP TO 4 MILLION TO SUPPORT ABOUT TEN
2	PROGRAMS. EACH WOULD SUPPORT A MINIMUM OF FIVE AND
3	UP TO TEN TRAININGS PER YEAR, AND THIS WOULD BE A
4	PROGRAM THAT WOULD CONTINUE FOR FIVE YEARS.
5	AND HERE ARE THE RECOMMENDATIONS BASED ON
6	THE SAME SCORING SYSTEM DESCRIBED BEFORE. THE
7	APPLICATIONS ARE RECOMMENDED FOR FUNDING IN TIER I.,
8	THERE ARE ZERO IN TIER II, AND ZERO IN TIER III.
9	MR. SHEEHY: THANK YOU, DR. SAMBRANO. SO
10	AT THIS POINT I WOULD EITHER TAKE A MOTION TO MOVE
11	ANY OF THE APPLICATIONS IN TIER I OUT OF THE
12	FUNDABLE CATEGORY OR A MOTION TO FUND ALL THE
13	APPLICATIONS IN TIER I.
14	DR. PRIETO: I'LL MAKE A MOTION TO FUND
15	ALL THE APPLICATIONS IN TIER I.
16	MR. SHEEHY: DO WE HAVE A SECOND?
17	MR. ROWLETT: SECOND.
18	MR. SHEEHY: ANY BOARD DISCUSSION?
19	DR. JUELSGAARD: SO THERE ARE SEVEN
20	PROGRAMS THAT ARE SEEKING FUNDING AS I SEE ON THE
21	AGENDA THAT WAS PROVIDED. BUT WHEN YOU LOOK AT THE
22	PRESENTATION, ESSENTIALLY IT SAYS THAT IN THE PAST
23	WE HAD NINE PARTICIPANTS, IF I'M RIGHT. SO
24	APPARENTLY TWO HAVE DROPPED OUT ALONG THE WAY. DO
25	WE HAVE ANY INSIGHT AS TO WHY THAT HAPPENED?
	16
	I D

1	DR. SAMBRANO: YES. IT'S A LITTLE BIT
2	MISLEADING. SO WHAT HAPPENS IS THERE ARE TWO
3	APPLICANTS THAT WERE IN TIER III, BUT THEY WITHDREW
4	THEIR APPLICATION BEFORE COMING TO THE BOARD. SO
5	OFTEN WHEN WE PROVIDE THE OUTCOMES FROM THE REVIEW
6	TO APPLICANTS, THEY HAVE THE OPTION TO WITHDRAW.
7	TWO OF THEM IN TIER III SELECTED TO DO THAT.
8	DR. JUELSGAARD: JUST TO FOLLOW UP ON THAT
9	THEN, GIL. SO IN THE PAST, THEN, IF I UNDERSTAND IT
10	CORRECTLY, THEY WERE FUNDED. SO THE TWO THAT
11	WITHDREW WERE FUNDED PREVIOUSLY, BUT NOW THEY'VE
12	WITHDRAWN; IS THAT RIGHT?
13	DR. SAMBRANO: I BELIEVE THAT IS THE CASE.
14	WE'RE CHECKING TO BE SURE. WE HAVE HAD, AT LEAST IN
15	THE BRIDGES, I REMEMBER, THERE WERE SOME NEW
16	PROGRAMS THAT CAME INTO THE MIX. I DON'T THINK THAT
17	WAS THE CASE FOR SPARK.
18	MR. JUELSGAARD: IF I'M CORRECT, AND I MAY
19	NOT BE, I APPRECIATE THAT, BUT DO WE KNOW WHY IN THE
20	PAST THEY HAVE BEEN APPROVED BUT NOW THEY HAVE
21	WITHDRAWN? DO WE KNOW WHAT'S CHANGED? AGAIN, IF
22	THESE ARE THE SAME TWO.
23	DR. SAMBRANO: WELL, THE REVIEW WAS A
24	LITTLE BIT DIFFERENT BECAUSE THERE ARE NEW ELEMENTS
25	THAT HAVE BEEN INTRODUCED INTO THE PROGRAM, SO THE
	17

DIRECT PATIENT ACTIVITIES AND OTHER ELEMENTS THAT
THEY NEEDED TO BE A PART OF THE PROGRAM. SO AT
LEAST A COUPLE THEM DID NOT DO WELL IN REFORMULATING
THEIR APPLICATION AND PRESENTING A NEW PROPOSAL THAT
WAS BETTER ALIGNED WITH THE PROGRAM THAT WE ENVISION
GOING FORWARD.
DR. JUELSGAARD: I'M SORRY THIS IS
REVISITING HISTORY JUST A LITTLE BIT. IN THE
BRIDGES PROGRAMS THERE WAS ONE PROGRAM THAT WAS A
TWO RATHER THAN A ONE AND PARTICIPATION WAS A MAJOR
CONCERN BY THE GWG REVIEWERS. IS THAT THE SAME
SITUATION, THAT IN THE PAST THEY WERE FUNDED, BUT
THIS TIME THEY WEREN'T FUNDED BECAUSE THEY BASICALLY
DIDN'T STAND OR DIDN'T MEET THE PARTICIPATION
REQUIREMENTS THAT WE WOULD HAVE LIKED TO HAVE SEEN?
DR. SAMBRANO: RIGHT. THE CRITICISMS
RELATED TO NEW ELEMENTS THAT WERE PART OF NOW THE
NEW PROGRAM. THIS IS FOR THE PATIENT ENGAGEMENT
ACTIVITIES, THE REVIEWERS DID NOT FEEL THEY WERE UP
TO PAR ON THAT.
DR. JUELSGAARD: ALL RIGHT. THANK YOU.
MR. SHEEHY: ANY FURTHER QUESTIONS FROM
MEMBERS OF THE BOARD? HEARING NONE, AMY, COULD YOU
CALL THE ROLL.
MS. CHEUNG: ANNE-MARIE DULIEGE. DAVID
18

1	HIGGINS.
2	DR. HIGGINS: YES.
3	MS. CHEUNG: STEPHEN JUELSGAARD.
4	MR. JUELSGAARD: YES.
5	MS. CHEUNG: SHERRY LANSING. KATHY
6	LAPORTE. LAUREN MILLER.
7	MS. MILLER: YES.
8	MS. CHEUNG: ADRIANA PADILLA.
9	DR. PADILLA: YES.
10	MS. CHEUNG: JOE PANETTA.
11	MR. PANETTA: YES.
12	MS. CHEUNG: FRANCISCO PRIETO.
13	DR. PRIETO: AYE.
14	MS. CHEUNG: ROBERT QUINT.
15	DR. QUINT: YES.
16	MS. CHEUNG: AL ROWLETT.
17	MR. ROWLETT: YES.
18	MS. CHEUNG: JEFF SHEEHY.
19	MR. SHEEHY: YES, EXCEPT FOR THOSE WITH
20	WHICH I HAVE A CONFLICT.
21	MS. CHEUNG: OS STEWARD.
22	DR. STEWARD: YES, EXCEPT FOR THOSE WITH
23	WHICH I HAVE A CONFLICT.
24	MS. CHEUNG: JONATHAN THOMAS.
25	CHAIRMAN THOMAS: YES.
	19

1	MS. CHEUNG: ART TORRES.
2	MR. TORRES: AYE.
3	MS. CHEUNG: DIANE WINOKUR.
4	MR. HARRISON: MOTION PASSES.
5	MR. SHEEHY: SO, CHAIRMAN THOMAS, THAT
6	CONCLUDES THE APPLICATION REVIEW SUBCOMMITTEE.
7	CHAIRMAN THOMAS: THANK YOU VERY MUCH, MR.
8	SHEEHY. ON TO ITEM 7, WHICH IS CONSIDERATION OF
9	AMENDMENTS TO THE GRANTS ADMINISTRATION POLICY.
10	GABE, WILL YOU PLEASE TAKE US THROUGH THOSE.
11	MR. THOMPSON: GOOD MORNING. AND THE CIRM
12	TEAM ARE HERE TO PRESENT CONSIDERATION OF ADOPTION
13	OF THE INTERIM GRANTS ADMINISTRATION POLICY FOR
14	DISCOVERY, TRANSLATION, AND EDUCATION PROJECTS.
15	JUST A REMINDER, THE GAP SETS OUT DETAILED
16	RULES FOR BOTH REVIEWING, AWARDING, AND THEN
17	MONITORING AWARDS APPROVED BY THE BOARD. AND IN
18	LIGHT OF THE FACT THAT WE JUST APPROVED TWO
19	EDUCATION PROGRAMS, AND WILL FOLLOW UP SOON WITH
20	TRANSLATION, WE NEED THESE POLICIES TO BE IN PLACE
21	JUST TO SUPPORT THOSE PROGRAMS. GIVEN THE TIMELINES
22	WHERE CIRM IS AVAILING ITSELF OF ITS STATUTORY
23	AUTHORITY TO ADOPT THE POLICY ON AN INTERIM BASIS,
24	WHICH ALLOWS THE POLICIES TO BE EFFECTIVE
25	IMMEDIATELY. AND THEN WE USE THE MAJORITY OF THE
	20

1	CALENDAR YEAR 2016 TO MAKE ADDITIONAL REVISIONS OR
2	EDITS TO THE POLICY. SO THE BOARD WILL HAVE
3	ADDITIONAL OPPORTUNITIES TO REVIEW THIS AND COMMENT
4	UPON FINAL ADOPTION OF THE POLICY LATER THIS YEAR.
5	SO WITH THAT STATED, I'LL GO OVER THE
6	CHANGES WE MADE. THE BASELINE FOR THE POLICY WAS
7	THE GRANTS ADMINISTRATION POLICY FOR CLINICAL STAGE
8	PROJECTS, AND THEN THE CHANGES ARE EITHER TO ALIGN
9	THE POLICY WITH WHAT WAS SPECIFIED IN THE PROGRAM
10	ANNOUNCEMENTS FOR DISCOVERY, TRANSLATION, AND
11	EDUCATION OR TO JUST SORT OF SIMPLIFY THE LANGUAGE
12	TO MAKE IT MORE CLEAR AND CONCISE.
13	TO GO THROUGH THESE, THE FIRST CHANGE IS
14	TO INTRODUCE THE CONCEPT OF A PROJECT MILESTONE. SO
15	MILESTONES ARE THE MARKER OF A PROJECT'S PROGRESS.
16	FOR CLINICAL STAGE PROJECTS, WE ESTABLISHED
17	OPERATIONAL MILESTONES WHICH WE CALL OBJECTIVE
18	EVENTS THAT, WHEN ACHIEVED, TRIGGER THE DISBURSEMENT
19	OF ADDITIONAL FUNDS. SO WE ARE GOING TO USE THE
20	CONCEPT OF OPERATIONAL MILESTONES FOR TRANSLATION
21	PROJECTS, BUT WE WILL USE THE CONCEPT OF PROJECT
22	MILESTONES FOR DISCOVERY AWARDS.
23	SO A PROJECT MILESTONE WOULD BE AN
24	OBJECTIVE EVENT ESTABLISHED BY CIRM. AND THOUGH ALL
25	THE FUNDS WOULD BE DISBURSED ON BASED ON TIME RATHER
	21

1	THAN THE ACCOMPLISHMENT OF A PROJECT MILESTONE,
2	CIRM, AT ITS SOLE DISCRETION, COULD REVISE PROJECT
3	ACTIVITIES, REALLOCATED RESOURCES, SUSPEND AND/OR
4	TERMINATE THE PROJECT IF AN AWARDEE FAILS TO
5	ACCOMPLISH A PROJECT MILESTONE WITHIN A REASONABLE
6	TIME.
7	SO WE ALSO REMOVED THE TERM "SUSPENSION
8	EVENT" GIVEN THAT THOSE WERE MAINLY FOR CLINICAL
9	STAGE PROGRAMS AND DON'T REALLY APPLY TO THE OTHER
10	PROGRAMS.
11	DR. JUELSGAARD: CAN I INTERRUPT YOU AT
12	THIS POINT. THIS IS STEVE JUELSGAARD. SO CAN YOU
13	EXPLAIN WHY YOU DECIDED TO INTRODUCE THE TERM
14	"PROJECT MILESTONES" INTO THE PROCESS RATHER THAN
15	THE WAY WE HAD IT BEFORE? WHAT WAS WRONG WITH WHAT
16	WE DID BEFORE WHICH WAS SIMPLY BASED ON TIME? WHAT
17	WAS WRONG WITH THAT APPROACH AS TO THE APPROACH THAT
18	YOU'RE PROPOSING NOW?
19	MR. THOMPSON: SO OUR THINKING HERE WAS
20	THAT IN EARLIER STAGE PROJECTS, THAT THERE WOULD BE
21	SOME ALLOWANCE OF THE CRITICAL PATH THAT THE
22	PROJECTS ARE GOING ON AND TO TRY TO GET TO THEIR
23	GOAL WITHIN A REASONABLE TIME PERIOD. AND SO WE
24	THOUGHT PROJECT MILESTONES WOULD BE MORE APPROPRIATE
25	IN THAT CASE AND BECAUSE THERE'S LESS OBJECTIVE
	22

1	EVENTS THAT ARE IN CRITICAL STAGE PROGRAMS. FOR
2	INSTANCE, WE BASE OPERATIONAL MILESTONES ON PERCENT
3	OF PATIENTS INVOLVED IN THE TRIAL. SO 50 PERCENT OF
4	PATIENTS ENROLLED WOULD BE ONE EXAMPLE, BUT TRYING
5	TO FIND A SIMILAR TYPE OF MILESTONE FOR TRANSLATION
6	AND DISCOVERY WHERE THE PATH WOULD BE DIFFERENT WE
7	FELT WARRANTED A DIFFERENT DEFINITION.
8	MR. HARRISON: IF I COULD JUST ELABORATE
9	BRIEFLY. THE FUNDS FOR THE DISCOVERY PROGRAMS,
10	WHICH ARE SMALLER, SHORTER AWARDS, WILL BE DISBURSED
11	ON A TIME BASIS, BUT WANTED TO ENSURE THAT WE HAD
12	SOME MECHANISM TO TERMINATE AN AWARD IF WE
13	DETERMINED THAT THE PROJECT HAD SIMPLY GONE OFF THE
14	TRACK. SO THE PROJECT MILESTONE, THE NEW DEFINITION
15	WE PROPOSE WOULD GIVE US THAT ABILITY.
16	DR. JUELSGAARD: ALL RIGHT. JAMES, I CAN
17	UNDERSTAND THAT, AND I CAN UNDERSTAND THAT GO OFF
18	THE TRACKS APPROACH, BUT THAT LANGUAGE IS NOT USED
19	IN WHAT I'M LOOKING AT RIGHT HERE. RATHER, IT'S
20	CIRM AT ITS DISCRETION CAN DO THIS.
21	SO CLINICAL MILESTONES TO ME ARE A VERY;
22	COMMON AND ACCEPTABLE APPROACH FOR DETERMINING
23	CONTINUED (UNINTELLIGIBLE) ALMOST ALL THE TIME IN
24	INDUSTRY AS A WAY OF WHEN ONE COMPANY OR
25	ORGANIZATION FINDS ANOTHER CLINICAL RESOURCE, BUT
	22

1	REALLY AREN'T USED SO MUCH IN THE DISCOVERY,
2	TRANSLATIONAL PHASE BECAUSE THERE'S SO MANY
3	POSSIBILITIES THAT CAN TURN UP ALONG THE WAY OF WHY
4	IT MIGHT BE MORE DIFFICULT, WHY ONE THING MIGHT LEAD
5	TO ANOTHER. SO I'M STILL STRUGGLING A LITTLE BIT
6	WITH THE NEED FOR CHANGING AT THIS POINT.
7	I UNDERSTAND THAT A MILESTONE IS MORE
8	OBJECTIVE AND THAT YOU HAVE A DATE IN MIND BY WHICH
9	SOMETHING HAS TO BE DONE. BUT AT THIS VERY, VERY
10	EARLY STAGE, TRYING TO PREDICT WHEN THINGS MIGHT
11	COME TO FRUITION IS JUST A LOT HARDER.
12	AND LET ME JUST SAY THIS. IN ADDITION TO
13	THIS, I FIND THAT IT'S JUST A LITTLE AWKWARD TO
14	DISCUSS THIS WITHOUT HAVING SOME OF OUR ACADEMIC OR
15	RESEARCH-ORIENTED COLLEAGUES ABLE TO ENGAGE IN THE
16	DISCUSSION BECAUSE THEY OBVIOUSLY HAVE A LOT OF
17	INSIGHT INTO THIS OR EXPERIENCE IN THIS. SO THOSE
18	OF US THAT ARE DISCUSSING THIS ARE LESS EXPERIENCED
19	POTENTIALLY IN THAT REGARD.
20	MY CONCERN IS JUST I DON'T KNOW HOW
21	MILESTONE ORIENTED THIS KIND OF ACTIVITY SHOULD
22	REALLY BE.
23	MR. HARRISON: STEVE, IF I COULD JUST
24	RESPOND BRIEFLY FIRST TO YOUR LAST POINT. ALL THE
25	MEMBERS OF THE BOARD CAN PARTICIPATE IN THIS
	2.4

1	DISCUSSION BECAUSE IT'S DISCUSSION ABOUT A STANDARD.
2	THEY'RE FREE TO WEIGH IN WITH THEIR EXPERIENCE. OUR
3	INTENT HERE REALLY WASN'T TO PUT CIRM IN A POSITION
4	WHERE IT WOULD TERMINATE AN AWARD SIMPLY BECAUSE IT
5	WAS TAKING MORE TIME OR WAS LEADING TO AN OUTCOME
6	OTHER THAN WHAT WE HAD HOPED FOR. WE RECOGNIZE THAT
7	THESE PROGRAMS ARE SMALL, THEY'RE SHORT IN TIME, AND
8	THEY'RE BASIC DISCOVERY. SO WE ANTICIPATE THAT
9	THERE WILL BE CHANGES IN DIRECTION.
10	WHAT WE'RE LOOKING FOR HERE IS A MEANS TO
11	TERMINATE A PROJECT WHERE THE GRANTEE HAS
12	EFFECTIVELY DECIDED TO TURN IN A WHOLE NEW DIRECTION
13	AND, IN EFFECT, A NEW PROJECT. WE WANT TO MAKE SURE
14	WE HAVE THE DISCRETION AT THAT POINT IN TIME TO PUT
15	A STOP TO IT. SO THIS IS NOT A POWER WE WOULD
16	ANTICIPATE USING FREQUENTLY. IT'S MORE A MEANS OF
17	TRYING TO KEEP THE PROGRAMS IN PROGRESS AND IN
18	CHECK.
19	MR. JUELSGAARD: THANKS. I YIELD THE
20	FLOOR.
21	DR. BOXER: I AM REALLY UNCLEAR ON HOW ONE
22	DEFINES A PROJECT MILESTONE AND HOW THAT RELATES TO
23	BASIC RESEARCH. SO I GUESS I WOULD AGREE WITH THE
24	PREVIOUS COMMENTS, THAT I DON'T REALLY UNDERSTAND
25	WHAT WAS WRONG WITH THE PREVIOUS PROCESS.
	25

1	AND I GUESS SO LET ME ASK. LET'S SAY
2	THERE'S AN UNFORESEEN RESULT OR DISCOVERY THAT
3	POTENTIALLY OPENS UP SOMETHING VERY INTERESTING. I
4	PRESUME THAT MUST HAVE HAPPENED IN THE PAST AND THAT
5	INVOLVES A DISCUSSION WITH CIRM SCIENTIFIC STAFF. I
6	MEAN HOW WOULD THAT HAVE BEEN HANDLED IN THE PAST.
7	DR. MILLS: SO THE PROBLEM WE HAVE IS WHAT
8	HAPPENS WHEN TWISTS OF FATE TAKE AN AWARD INTO A
9	SCOPE THAT IS NOT IS NO LONGER THE PROJECT THAT
10	THE GWG REVIEWED AND IS NO LONGER THE PROJECT THAT
11	THE ICOC FUNDED. AND THAT HAPPENS FAIRLY OFTEN. SO
12	WE HAVE, AND I'LL LET JAMES TALK MORE ABOUT IT, BUT
13	WE HAVE SORT OF CONTRACTUAL OBLIGATIONS TO MAKE SURE
14	WE FUND THE RESEARCH THAT YOU AS THE BOARD APPROVED
15	AND THE GWG RECOMMENDED. AND WHAT WE CAN'T HAVE ARE
16	PEOPLE PUTTING IN ONE APPLICATION, STARTING ON A
17	PROJECT, DECIDE THEY WANT TO DO SOMETHING COMPLETELY
18	DIFFERENT, AND THEN USE OUR FOUNDS TO DO THAT IN AN
19	UNREVIEWED FASHION.
20	THIS IS A MECHANISM BY WHICH WE WOULD BE
21	ABLE TO CONTROL THAT. BUT I WOULD SAY THE FIRST
22	THING WE DID, BECAUSE OUR GOAL IS TO TRY TO GET
23	THESE THERAPIES ACCELERATED TO THE PATIENT, THE
24	FIRST THING WE DID, AS YOU GUYS WILL ALL RECALL AND
25	TOOK PART IN, WAS SETTING UP MECHANISMS WHEREBY A
	26
25	
	, U

1	NEW DISCOVERY POPPED UP, YOU WEREN'T WONDERING WHEN
2	YOU COULD REAPPLY OR IF YOU COULD REAPPLY IN A
3	TIMELY FASHION. SINCE WE PUT BOTH THE DISCOVERY AND
4	THE TRANSLATIONAL PROGRAMS ON REVIEW CYCLES EVERY
5	SIX MONTHS, WHILE ONE PROGRAM MAY NEED TO BE WINDED
6	DOWN BECAUSE THE DIRECTION HAS CHANGED BASED ON THE
7	MECHANISMS THAT JAMES AND GABE PROPOSED TODAY, THE
8	OTHER ONE, IF FOUND TO BE MERITORIOUS BY THE GWG AND
9	THE BOARD, ARE CONTINUOUSLY AND COMPLETELY AVAILABLE
10	WITHOUT ANY DELAY OR TIME GAP IN FUNDING.
11	SO THAT'S THE BALANCE WE'RE TRYING TO
12	STRIKE HERE, MAKING SURE THAT CIRM IS ABLE TO DO
13	BUSINESS IN A TIMELY FASHION THAT DOESN'T DELAY THE
14	RESEARCH, BUT ALSO GIVING US THE PROPER GOVERNANCE
15	OVERSIGHT TO MAKE SURE THAT WHAT WE ACTUALLY
16	APPROVED FOR FUNDING GOES ON AND IS ACTUALLY THE
17	WORK THAT'S GETTING DONE.
18	DR. STEWARD: THIS IS OS. COULD I
19	COMMENT?
20	CHAIRMAN THOMAS: ABSOLUTELY.
21	DR. STEWARD: JUST TO MAYBE ALLAY SOME OF
22	CONCERNS, THIS IS REALLY NOT ALL THAT MUCH DIFFERENT
23	THAN WHAT GOES ON AT NIH. EVERY YEAR NIH GRANTEES
24	SUBMIT PROGRESS REPORTS THAT ARE REVIEWED BY THE
25	PROGRAM OFFICERS. AND NIH HAS THE OPTION AT THAT
	27

1	POINT IN TIME TO LOOK AT WHAT'S BEEN DONE AND WHAT'S
2	PLANNED AND MAKE A DETERMINATION OF WHETHER THE
3	RESEARCH IS OUT OF SCOPE FOR THE ORIGINAL PROPOSAL.
4	AND THERE ARE OCCASIONALLY DECISIONS MADE ALONG
5	THOSE LINES.
6	NOW, I WOULD SAY THAT I THINK THAT MAYBE
7	CIRM IS A LITTLE BIT MORE FOCUSED IN ITS ATTACK ON
8	THE PROBLEMS AND MIGHT BE MORE LIKELY TO DETERMINE
9	SOMETHING AS BEING OUT OF SCOPE THAN NIH MIGHT BE,
10	BUT I DON'T THINK INVESTIGATORS WILL FIND THAT ALL
11	THAT DIFFERENT OR PARTICULARLY CONCERNING. THANK
12	YOU.
13	DR. JUELSGAARD: ONE LAST QUESTION. I'VE
14	HEARD EXACTLY THE TERM YOU USED WHEN YOU DESCRIBED
15	THIS, BUT YOU INDICATED THAT ALONG THE WAY WE'VE HAD
16	SOME ISSUES WITH SOME NUMBER, WHICH I ASSUME IS MORE
17	LIKELY THE CASE BASED ON WHAT OS JUST SAID WITH THE
18	NIH. WHAT PERCENTAGE OF TIME OR WHAT SPECIFICALLY
19	HAPPENED OR WHAT PERCENTAGE OF TIME DID THESE THINGS
20	HAPPEN THAT CAUSED THIS ISSUE TO COME ON THE FORE
21	WITH THE DESIRE TO CHANGE THE APPROACH? SO WHAT
22	LIES BEHIND THIS?
23	DR. MILLS: SO THEY COME IN ALL DIFFERENT
24	SORT OF VARIETIES OR SEVERITY, BUT THERE WAS A
25	NUMBER THROWN OUT, I WANT TO SAY, 80 PERCENT RANGE.

1	SO APPROXIMATELY 80 PERCENT OF THIS STAGE
2	APPLICATION THAT COMES BEFORE US HAS ONE OR MULTIPLE
3	CHANGE REQUESTS, WHICH ARE IRONICALLY CALLED PRIOR
4	APPROVAL REQUESTS, SOMETHING OF WHICH LIKE 90
5	PERCENT ARE GIVEN TO US AFTER THE FACT.
6	DR. JUELSGAARD: SO, AGAIN, THOSE 90
7	PERCENT OF THE CASES CIRM WOULD EVALUATE WHETHER TO
8	CONTINUE THE FUNDING OR TO STOP IS. THAT WHAT
9	YOU'RE SAYING?
10	DR. MILLS: YES, BECAUSE IT'S A CHANGE.
11	NOW, TO TAKE THAT EVEN FURTHER, MOST OF THE TIME,
12	THE VAST MAJORITY OF THE TIME, EVEN IF THEY'RE
13	SUBMITTED AFTER THE FACT, THE PRIOR APPROVAL REQUEST
14	IS APPROVED.
15	DR. JUELSGAARD: OKAY.
16	CHAIRMAN THOMAS: ANY OTHER QUESTIONS
17	ALONG THESE LINES? OKAY. CAN YOU CONTINUE?
18	MR. THOMPSON: SO THE NEXT REVISION WE
19	MADE WAS UNDER APPLICATION REVIEW AND SCORING
20	SECTION. WE'RE SIMPLIFYING THIS LANGUAGE TO JUST
21	DESIGNATE WHETHER AN APPLICATION IS EITHER
22	RECOMMENDED FOR FUNDING OR NOT RECOMMENDED FOR
23	FUNDING. WE PREVIOUSLY HAD A MUCH MORE DETAILED
24	SECTION DESCRIBING THE FUNDING. BUT GIVEN THE BOARD
25	APPROVED AMENDMENT TO THE GWG BYLAWS THAT DEFINE THE

1	SCORING FOR NONCLINICAL PROGRAMS, WE DIDN'T NEED TO
2	INCLUDE THAT MUCH DETAIL WITHIN THE GAP ITSELF.
3	THE NEXT SECTION IS UNDER UNALLOWABLE
4	COSTS. CIRM IS PROPOSING TO ALLOW MEMBERSHIP DUES
5	TO BE CHARGED TO CIRM AWARDS WHEN REASONABLY
6	ALLOCATED TO THE PROJECT. MEMBERSHIP DUES HAD BEEN
7	PREVIOUSLY UNALLOWABLE TO ALIGN WITH NIH POLICY, BUT
8	OUR COMPLIANCE SECTION HAS REVEALED THERE COULD BE
9	ACTUALLY JUSTIFIABLE REASONS TO CHARGE MEMBERSHIP TO
10	A CIRM AWARD FOR PROJECT PERSONNEL WHO ARE WORKING
11	ON A PROJECT. SO THE DUES ARE OFTEN ASSOCIATED WITH
12	REGISTRATION AT A CONFERENCE, WHICH IS AN
13	UNALLOWABLE (INTERRUPTION BY A CELL PHONE).
14	MEMBERSHIP DUES SHOULD BE ALLOWABLE WHEN THE PROJECT
15	ITSELF CAN REASONABLY ALLOCATE THE COST TO CIRM
16	PROJECTS.
17	MR. SHEEHY: JUST FOR FOLKS MAKE SURE
18	EVERYBODY IS CLEAR. THE SCORING SYSTEM WILL BE 85
19	AND ABOVE IS FUNDABLE, 84 AND BELOW IS NOT
20	RECOMMENDED FOR FUNDING, RIGHT. SO WE MOVED TO TWO
21	TIERS. SO WHAT WE HAD TODAY WE WILL NEVER SEE
22	AGAIN. THIS WOULD BE SEPARATE FOR THE ONE, TWO,
23	THREE SCORING THAT WE DO IN THE CLINICAL PROGRAMS.
24	JUST SO EVERYBODY IS CLEAR ABOUT THE CHANGE OF THE
25	SCORING SYSTEM (UNINTELLIGIBLE).
	20

30

1	MR. HARRISON: ONE POINT TO ADD TO THAT,
2	JEFF. ONE OF THE REASONS WE DIDN'T WANT TO INCLUDE
3	THAT LEVEL OF DETAIL IN THE GAP IS IT'S ALREADY SET
4	FORTH IN THE BYLAWS. THE BYLAWS ARE AN INTERNAL
5	SORT OF DOCUMENT, AND THE BOARD CAN CHANGE THE
6	BYLAWS AND THOSE CHANGES GO INTO EFFECT IMMEDIATELY.
7	ONCE WE PUT IT INTO THE GRANTS ADMINISTRATION
8	POLICY, IT BECOMES SUBJECT TO THE ADMINISTRATIVE
9	PROCEDURE ACT, WHICH WOULD MEAN WE'D NEED TO GO
10	THROUGH A LENGTHY PROCESS TO CHANGE WHAT IS
11	EFFECTIVELY AN INTERNAL POLICY.
12	MR. SHEEHY: THANK YOU.
13	MR. THOMPSON: THE NEXT SECTION IS
14	POST-PROJECT ALLOWABLE COSTS. THIS WAS A CONCEPT WE
15	INTRODUCED FOR CLINICAL STAGE PROGRAMS TO
16	INCENTIVIZE THE EFFICIENT USE OF CIRM FUNDS WHICH
17	ALLOWED, OF THE PROJECTS HAD REMAINING CIRM FUNDS AT
18	THE END OF THEIR PROJECT, TO EITHER REDUCE THE
19	ACTUAL CO-FUNDING TO AN AMOUNT THAT WAS LOWER THAN
20	WHAT WAS ORIGINALLY REQUIRED ON THE AWARD OR TO FUND
21	A PROJECT AT THE AWARDEE INSTITUTION THAT FURTHERS
22	CIRM'S MISSION SUBJECT TO CIRM'S PRIOR APPROVAL AND
23	SUBJECT TO CIRM REGULATIONS AND AUDIT, OR TO RETURN
24	THE FUNDS TO CIRM WITHIN 30 DAYS OF THE DEADLINE FOR
25	FINAL FINANCIAL REPORTS.

1	WE'RE GOING TO EXTEND THE POLICY FOR
2	POST-PROJECT ALLOWABLE COSTS FOR ALL TRANSLATION AND
3	DISCOVERY PROJECTS. SO IF ANY OF THOSE PROJECTS
4	HAVE AVAILABLE FUNDING, THEY CAN SUBMIT TO CIRM A
5	PRIOR APPROVAL TO USE THAT FUNDING FOR CIRM MISSION
6	CRITICAL PROJECTS SUBJECT TO REVIEW.
7	THE FINAL SECTION IS UNDER FAILURE OF
8	COMPLIANCE. SO UNDER THE FAILURE OF COMPLIANCE
9	SECTION, WE SET FORTH THE ACTIONS CIRM CAN TAKE IF
10	ONE OR MORE OF THE CONDITIONS OF THE AWARD ARE
11	VIOLATED. AND IN THIS SECTION WE PROPOSE TO EXPAND
12	THE LIST TO INCLUDE CONSIDERATION OF PAST
13	PERFORMANCE. AND WE ADDED THIS LANGUAGE TO ALIGN
14	WITH THE POLICY MODIFICATIONS UNDER CIRM 2.0
15	APPROVED BY THE BOARD IN DECEMBER.
16	THAT'S THE EXTENT OF THE CHANGES WE'D LIKE
17	TO MAKE. AGAIN, IF YOU WERE TO ADOPT THE POLICY
18	TODAY, IT WOULD GO INTO INTERIM STATUS, AND YOU HAVE
19	ADDITIONAL TIME IN 2016 TO PROVIDE COMMENTS AND
20	REVIEW THE POLICY.
21	CHAIRMAN THOMAS: THANK YOU VERY MUCH,
22	GABE. DO I HEAR A MOTION TO APPROVE THESE INTERIM
23	AMENDMENTS?
24	DR. FRIEDMAN: I MAKE THE MOTION.
25	CHAIRMAN THOMAS: THANK YOU, DR. FRIEDMAN.
	32

	DARRISTERS REFORTING SERVICE
1	DO I HEAR A SECOND?
2	MR. TORRES: SECOND DR. FRIEDMAN'S MOTION.
3	CHAIRMAN THOMAS: SECONDED MORE OR LESS
4	SIMULTANEOUSLY BY MR. SHEEHY AND SENATOR TORRES.
5	ANY FURTHER DISCUSSION ON THIS ITEM? AMY, PLEASE
6	CALL THE ROLL.
7	MS. CHEUNG: DAVID BRENNER.
8	DR. BRENNER: YES.
9	MS. CHEUNG: LINDA BOXER.
10	DR. BOXER: YES.
11	MS. CHEUNG: KEN BURTIS.
12	DR. BURTIS: YES.
13	MS. CHEUNG: ANNE-MARIE DULIEGE.
14	DR. DULIEGE: YES.
15	MS. CHEUNG: MICHAEL FRIEDMAN.
16	DR. FRIEDMAN: YES.
17	MS. CHEUNG: JUDY GASSON.
18	DR. GASSON: YES.
19	MS. CHEUNG: SAM HAWGOOD. DAVID HIGGINS.
20	DR. HIGGINS: YES.
21	MS. CHEUNG: STEPHEN JUELSGAARD.
22	MR. JUELSGAARD: YES.
23	MS. CHEUNG: SHERRY LANSING. KATHY
24	LAPORTE. BERT LUBIN.
25	DR. LUBIN: YES.
	33


	_	
1		MS. CHEUNG: SHLOMO MELMED.
2		DR. MELMED: YES.
3		MS. CHEUNG: LAUREN MILLER.
4		MS. MILLER: YES.
5		MS. CHEUNG: ADRIANA PADILLA.
6		DR. PADILLA: YES.
7		MS. CHEUNG: JOE PANETTA.
8		MR. PANETTA: YES.
9		MS. CHEUNG: ROBERT PRICE.
10		DR. PRICE: YES.
11		MS. CHEUNG: FRANCISCO PRIETO.
12		MS. CHEUNG: AYE.
13		MS. CHEUNG: CARMEN PULIAFITO. ROBERT
14	QUINT.	
15		DR. QUINT: YES.
16		MS. CHEUNG: AL ROWLETT.
17		MR. ROWLETT: YES.
18		MS. CHEUNG: JEFF SHEEHY.
19		MR. SHEEHY: YES.
20		MS. CHEUNG: OS STEWARD.
21		DR. STEWARD: YES.
22		MS. CHEUNG: JONATHAN THOMAS.
23		CHAIRMAN THOMAS: YES.
24		MS. CHEUNG: ART TORRES.
25		MR. TORRES: AYE.
		34
		J <del>+</del>

1	MS. CHEUNG: KRISTINA VUORI.
2	DR. VUORI: YES.
3	MS. CHEUNG: DIANE WINOKUR.
4	MR. HARRISON: MOTION PASSES.
5	CHAIRMAN THOMAS: THANK YOU. THAT
6	CONCLUDES THE ACTION ITEMS ON THE AGENDA. I WILL
7	ASK. I BELIEVE THERE ARE NO MEMBERS OF THE PUBLIC
8	AT ANY OF THE SITES, BUT JUST FOR THE SAKE OF
9	COMPLETENESS, ASK IF THERE IS ANYBODY WHO WANTS TO
10	COMMENT AMONGST THE MEMBERS OF THE PUBLIC AT THIS
11	TIME. HEARING NONE, THAT CONCLUDES TODAY'S MEETING.
12	THANK YOU VERY MUCH, EVERYBODY. HAVE A WONDERFUL
13	REST OF THE DAY.
14	(THE MEETING WAS THEN CONCLUDED AT 11:52 A.M.)
15	
16	
17	
18	
19	
20	
21	
22	
23	
24	
25	
	25
	35

#### REPORTER'S CERTIFICATE

I, BETH C. DRAIN, A CERTIFIED SHORTHAND REPORTER IN AND FOR THE STATE OF CALIFORNIA, HEREBY CERTIFY THAT THE FOREGOING TRANSCRIPT OF THE TELEPHONIC PROCEEDINGS BEFORE THE INDEPENDENT CITIZEN'S OVERSIGHT COMMITTEE AND THE APPLICATION REVIEW SUBCOMMITTEE OF THE CALIFORNIA INSTITUTE FOR REGENERATIVE MEDICINE IN THE MATTER OF ITS REGULAR MEETING HELD ON JANUARY 19, 2016, WAS HELD AS HEREIN APPEARS AND THAT THIS IS THE ORIGINAL TRANSCRIPT THEREOF AND THAT THE STATEMENTS THAT APPEAR IN THIS TRANSCRIPT WERE REPORTED STENOGRAPHICALLY BY ME AND TRANSCRIBED BY ME TO THE BEST O MY ABILITY TO HEAR AND UNDERSTAND THE TELEPHONIC TRANSMISSION. I ALSO CERTIFY THAT THIS TRANSCRIPT IS A TRUE AND ACCURATE RECORD OF THE PROCEEDING.

BETH C. DRAIN, CSR 7152 BARRISTERS' REPORTING SERVICE 160 S. OLD SPRINGS ROAD SUITE 270 ANAHEIM, CALIFORNIA (714) 444-4100



160 S. OLD SPRINGS ROAD, SUITE 270, ANAHEIM, CALIFORNIA 92808 1-800-622-6092 1-714-444-4100 EMAIL: DEPO@DEPO1.COM